Form 4: ATAI Life Sciences Director Andrea Heslin Smiley Granted 103,000 Stock Options

ATAI Life Sciences N.V. Director Andrea Heslin Smiley was granted 103,000 stock options with an exercise price of $2.25, vesting by June 26, 2026, or the day before the next annual meeting.

Summary

• Andrea Heslin Smiley, a Director of ATAI Life Sciences N.V. (ATAI), was granted 103,000 stock options.
• The options have an exercise price of $2.25 per common share.
• The transaction date for this grant was June 26, 2025.
• These options are set to expire on June 26, 2035.
• Vesting will occur on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026.
• Following this transaction, Andrea Heslin Smiley beneficially owns 103,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive. While a routine filing, the grant of options to a director aligns their interests with shareholders, which is generally viewed favorably as an incentive for long-term performance. There are no negative financial implications reported in this specific filing beyond potential future dilution from exercise.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $2.25 provides a clear benchmark for future stock performance required for the options to be in-the-money.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if the options are exercised.

Risks

• Potential future dilution of common shares if the 103,000 stock options are exercised.
• The value of the options is dependent on the future market price of ATAI common shares exceeding the $2.25 exercise price.

Future Outlook

The stock options granted to Director Andrea Heslin Smiley are set to vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026, and will expire on June 26, 2035, indicating a long-term incentive structure.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant to a director, which is a common practice in the biotechnology and pharmaceutical industry to align management and board interests with shareholder value creation. Such grants are standard components of executive and director compensation packages across publicly traded companies.

Related Party Transactions

• Grant of 103,000 stock options to Andrea Heslin Smiley, a Director of ATAI Life Sciences N.V., which constitutes a transaction with a related party.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of director's interests with shareholder value.
• Director (Andrea Heslin Smiley): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• Vesting of the 103,000 stock options on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026.
• Potential exercise of the stock options by Andrea Heslin Smiley before the expiration date of June 26, 2035.

Key Dates

Keywords

ATAI Life Sciences, ATAI, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Andrea Heslin Smiley, SEC Filing